TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING RESEARCH & DEVELOPMENT EXPENDITURE

4.2.2 RISING DRUG DEVELOPMENT OUTSOURCING

4.3 RESTRAINTS

4.3.1 STRINGENT REGULATORY POLICIES AND COSTS ASSOCIATED TO DRUG DISCOVERY

4.4 OPPORTUNITY

4.4.1 TECHNOLOGICAL ADVANCEMENTS IN DRUG DISCOVERY

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)

5.1.2 SERVICE CUSTOMIZATION

5.1.2.1 R&D

5.1.2.2 GOOD LABORATORY PRACTICES (GLP)

5.1.3 CUSTOMER PURCHASE SUPPORT

5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 COVID-19 IMPACT ON THE DRUG DISCOVERY SERVICES MARKET

5.3.1 IMPACT ON R&D

5.3.2 IMPACT ON PRICING

5.3.3 IMPACT ON MARKET GROWTH

6 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE

6.1 OVERVIEW

6.2 SMALL MOLECULE DRUG

6.3 BIOLOGICS DRUG

7 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY TYPES OF SERVICES

7.1 OVERVIEW

7.2 DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES

7.3 PHARMACEUTICAL SERVICES

7.4 MEDICINAL CHEMISTRY

7.5 BIOLOGICAL SERVICES

7.6 MEDICATION

8 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

8.1 OVERVIEW

8.2 ONCOLOGY

8.3 CARDIOVASCULAR DISEASES

8.4 RESPIRATORY DISEASES

8.5 DIABETES

8.6 OTHERS

9 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY TECHNOLOGY

9.1 OVERVIEW

9.2 HIGH THROUGHPUT SCREENING

9.3 BIOCHIPS

9.4 PHARMACOGENOMICS AND PHARMACOGENETICS

9.5 METABOLOMICS

9.6 OTHERS

10 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY END USER

10.1 OVERVIEW

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.3 RESEARCH & ACADEMIC INSTITUTES

10.4 OTHERS

11 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 US

11.2.2 CANADA

11.3 EUROPE

11.3.1 GERMANY

11.3.2 FRANCE

11.3.3 UK

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 JAPAN

11.4.3 INDIA

11.4.4 AUSTRALIA

11.4.5 SOUTH KOREA

11.4.6 REST OF ASIA-PACIFIC

11.5 REST OF THE WORLD

11.5.1 MIDDLE EAST

11.5.2 AFRICA

11.5.3 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 OVERVIEW

12.2 COMPETITIVE BENCHMARKING

12.3 MAJOR GROWTH STRATEGY IN DRUG DISCOVERY SERVICES MARKET

12.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN DRUG DISCOVERY SERVICES MARKET

12.5 KEY DEVELOPMENTS & GROWTH STRATEGIES

12.5.1 SERVICE LAUNCH

12.5.2 MERGERS & ACQUISITIONS

12.5.3 PARTNERSHIP/COLLABORATION

12.6 MAJOR PLAYERS SALES ANALYSIS

12.6.1 SALES & OPERATING INCOME, 2021 (USD MILLION)

12.6.2 MAJOR PLAYERS R&D ANALYSIS, 2021 (USD MILLION)

13 COMPANY PROFILE

13.1 THERMO FISHER SCIENTIFIC INC.

13.1.1 COMPANY OVERVIEW

13.1.2 FINANCIAL OVERVIEW

13.1.3 SERVICES OFFERED

13.1.4 KEY DEVELOPMENTS

13.1.5 SWOT ANALYSIS

13.1.6 KEY STRATEGIES

13.2 ARAGEN LIFE SCIENCES PVT. LTD.

13.2.1 COMPANY OVERVIEW

13.2.2 FINANCIAL OVERVIEW

13.2.3 SERVICES OFFERED

13.2.4 KEY DEVELOPMENTS

13.2.5 KEY STRATEGIES

13.3 PIRAMAL PHARMA SOLUTIONS

13.3.1 COMPANY OVERVIEW

13.3.2 FINANCIAL OVERVIEW

13.3.3 SERVICES OFFERED

13.3.4 KEY DEVELOPMENTS

13.3.5 KEY STRATEGIES

13.4 CURIA GLOBAL, INC.

13.4.1 COMPANY OVERVIEW

13.4.2 FINANCIAL OVERVIEW

13.4.3 SERVICES OFFERED

13.4.4 KEY STRATEGIES

13.5 CHARLES RIVER LABORATORIES

13.5.1 COMPANY OVERVIEW

13.5.2 FINANCIAL OVERVIEW

13.5.3 SERVICES OFFERED

13.5.4 KEY DEVELOPMENTS

13.5.5 SWOT ANALYSIS

13.5.6 KEY STRATEGIES

13.6 EUROFINS SCIENTIFIC

13.6.1 COMPANY OVERVIEW

13.6.2 FINANCIAL OVERVIEW

13.6.3 SERVICES OFFERED

13.6.4 KEY DEVELOPMENTS

13.6.5 SWOT ANALYSIS

13.6.6 KEY STRATEGIES

13.7 IQVIA

13.7.1 COMPANY OVERVIEW

13.7.2 FINANCIAL OVERVIEW

13.7.3 SERVICES OFFERED

13.7.4 KEY DEVELOPMENTS

13.7.5 SWOT ANALYSIS

13.7.6 KEY STRATEGIES

13.8 EVOTEC

13.8.1 COMPANY OVERVIEWS

13.8.2 FINANCIAL OVERVIEW

13.8.3 SERVICES OFFERED

13.8.4 KEY DEVELOPMENTS

13.8.5 KEY STRATEGIES

13.9 WUXI APPTEC CO., LTD.

13.9.1 COMPANY OVERVIEW

13.9.2 FINANCIAL OVERVIEW

13.9.3 SERVICES OFFERED

13.9.4 KEY DEVELOPMENTS

13.9.5 SWOT ANALYSIS

13.9.6 KEY STRATEGIES

13.10 LABORATORY CORPORATION OF AMERICA HOLDINGS

13.10.1 COMPANY OVERVIEW

13.10.1 FINANCIAL OVERVIEW

13.10.2 SERVICES OFFERED

13.10.3 KEY DEVELOPMENTS

13.10.4 KEY STRATEGIES

13.11 SELVITA

13.11.1 COMPANY OVERVIEW

13.11.2 FINANCIAL OVERVIEW

13.11.3 SERVICES OFFERED

13.11.4 KEY DEVELOPMENTS

13.11.5 SWOT ANALYSIS

13.11.6 KEY STRATEGIES

13.12 SYGNATURE DISCOVERY

13.12.1 COMPANY OVERVIEW

13.12.2 FINANCIAL OVERVIEW

13.12.3 SERVICES OFFERED

13.12.4 KEY DEVELOPMENTS

13.12.5 SWOT ANALYSIS

13.12.6 KEY STRATEGIES

13.13 SYMERES

13.13.1 COMPANY OVERVIEW

13.13.2 FINANCIAL OVERVIEW

13.13.3 SERVICES OFFERED

13.13.4 KEY DEVELOPMENTS

13.13.5 SWOT ANALYSIS

13.13.6 KEY STRATEGIES

13.14 NUCHEM SCIENCES INC.

13.14.1 COMPANY OVERVIEW

13.14.2 FINANCIAL OVERVIEW

13.14.3 SERVICES OFFERED

13.14.4 KEY STRATEGIES

13.15 PARAZA PHARMA, INC.

13.15.1 COMPANY OVERVIEW

13.15.2 FINANCIAL OVERVIEW

13.15.3 SERVICES OFFERED

13.15.4 KEY DEVELOPMENTS

13.15.5 KEY STRATEGIES

14 APPENDIX

14.1 REFERENCES

14.2 RELATED REPORTS